Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Drugs. 2007 Apr;18(4):363-70.

Histone deacetylase inhibitors for epigenetic therapy of cancer.

Author information

1
Department of Medicinal Chemistry, Institut Curie, Paris, France. claude.monneret@curie.fr

Erratum in

  • Anticancer Drugs. 2007 Jun;18(5):219.

Abstract

Histone acetylation and histone deacetylation play key roles in the epigenetic regulation. Thus, inhibition of deacetylation controlled by histone deacetylases may result in chromatin remodeling, upregulation of key tumor repressor genes, differentiation or apoptosis. Therefore many naturally occurring and synthetic histone deacetylase inhibitors have been shown to display potent anticancer activities in preclinical studies. The exact mechanism by which histone deacetylases exert their effect, however, is still obscure; in any case it is more complicated than originally understood. Although several representatives of this novel class of therapeutic agents are currently at early stages of clinical development, rational design leading to highly selective histone deacetylase inhibitors against histone deacetylase isoforms will not only probably offer more potent anticancer drugs, but also critical insights into their mechanism of action.

PMID:
17351388
DOI:
10.1097/CAD.0b013e328012a5db
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center